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Cardiovascular risk factors in women who had hypertensive
disorders late in pregnancy: a cohort study
Wietske Hermes, MD; Arie Franx, MD, PhD; Maria G. van Pampus, MD, PhD; Kitty W. M. Bloemenkamp, MD, PhD;
Michiel L. Bots, MD, PhD; Joris A. van der Post, MD, PhD; Martina Porath, MD, PhD; Gabrielle A. E. Ponjee, MD, PhD;
Jouke T. Tamsma, MD, PhD; Ben Willem J. Mol, MD, PhD; Christianne J. M. de Groot, MD, PhDOBJECTIVE: The purpose of this study was to determine cardiovascular
risk factors in women with a history of hypertensive pregnancy disor-
ders at term (HTP) 2.5 years after pregnancy.
STUDY DESIGN: In a multicenter cohort study in The Netherlands from
June 2008 through November 2010, cardiovascular risk factors were
compared between women with a history of HTP (HTP cohort, n 306)
and women with a history of normotensive pregnancies at term (NTP
cohort, n99). HTPwomenhad participated in a randomized, longitudinal
trial assessing the effectiveness of induction of labor in women with hyper-
tensive pregnancy disorders at term. All women were assessed 2.5 years
after pregnancy for blood pressure, anthropometrics, glucose, glycosylated
hemoglobin, insulin, homeostatic model assessment score, total choles-
terol, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-
reactive protein, andmicroalbumin andmetabolic syndrome.
study. Am J Obstet Gynecol 2013;208:474.e1-8.
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474.e1 American Journal of Obstetrics& Gynecology JUNE 2013RESULTS: After a mean follow-up period of 2.5 years, hypertension
(HTP, 34%; NTP, 1%; P .001) and metabolic syndrome (HTP, 25%;
NTP, 5%; P .001) weremore prevalent in HTPwomen compared with
NTP women. HTP women had significantly higher systolic and diastolic
blood pressure, higher body mass index, and higher waist circumfer-
ence. Glucose, glycosylated hemoglobin, insulin, homeostatic model
assessment score, total cholesterol, triglycerides, and high-sensitivity
C-reactive protein levels were significantly higher and high-density lipo-
protein cholesterol was significantly lower in HTP women.
CONCLUSION: In women with a history of HTP, hypertension and meta-
bolic syndrome are more common, and they have higher levels of bio-
chemical cardiovascular risk factors 2.5 years after pregnancy.
Key words: cardiovascular risk factors, cohort study, gestational
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lCardiovascular disease (CVD) isthe leading cause of death in
omen in the Western world.1 Heart
isease symptoms in women are differ-
nt from symptoms in men and diag-
ostic tools in women seem to be less
ensitive and specific than for men.2
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www.AJOG.org Obstetrics Researchfects, thus identifying women at a young
age at increased risk for cardiovascular
events.13 Determining cardiovascular
risk factors in women who respond to
this stress test with transient hyperten-
sion could be an opportunity for identi-
fying high-risk women for early preven-
tion of modifiable cardiovascular risk
factors.14,15Until now,most studies have
focused on severe preterm preeclampsia,
which is a rare disease. Most hyperten-
sive disorders develop  36 weeks’ ges-
tation. Therefore, we conducted a fol-
low-up studyof a randomized controlled
trial in The Netherlands to assess cardio-
vascular risk factors inwomenwith a his-
tory of hypertensive pregnancy disorders
at term (HTP) 2.5 years after their com-
plicated pregnancy.
MATERIALS AND METHODS
Ethics statement
The follow-up study was approved by
the institutional reviewboardof theUni-
versity of Leiden and locally approved by
the hospital board of the participating
hospitals. The study protocol has previ-
ously been published.16 The current
study is a follow-up of the Hypertension
and Preeclampsia Intervention Trial at
Term (HYPITAT) study (trial registra-
tion: ISRCTN08132825).17
Participants
Hypertension in pregnancy cohort
From October 2005 through March
2008, the HYPITAT study,17 a multi-
enter, parallel, open-label randomized
ontrolled trial of induction of labor
s expectant management, included
omen with gestational hypertension or
reeclampsia at term (n  1153). At
aseline (randomization), these women
onsented to be contacted 2.5 years after
heir delivery to participate in the fol-
ow-up study.
heHYPITAT study
he HYPITAT study evaluated whether
nduction of labor improved maternal
utcome in women with gestational hy-
ertension or preeclampsia at term and
ncluded women with a singleton preg-
ancy at a gestational age between 360
and 410 weeks. The diastolic blood
ressure thresholds for inclusion in the aYPITAT study differed between gesta-
ional hypertension and preeclampsia as
iastolic blood pressure of 90 mm Hg
ithout proteinuria was discussed and
onsidered toomild and trivial for inclu-
ion in the HYPITAT trial. Therefore,
estational hypertensionwas defined as a
iastolic blood pressure of 95 mm Hg
easured on 2 occasions at least 6 hours
part without proteinuria. Preeclampsia
as defined as diastolic bloodpressure of
90mmHgmeasured on 2 occasions at
east 6 hours apart, combined with pro-
einuria (2 occurrences of protein on a
ipstick,300 mg total protein within a
4-hour urine collection, or ratio of pro-
ein to creatinine30 mg/mmol).
Other exclusion criteria included:
ntihypertensive medication use for
hronic hypertension, diabetes mellitus,
estational diabetes treated with insulin,
enal disease, heart disease, previous cesar-
an section,HELLP syndrome (hemolysis,
levated liver enzymes, and low platelets),
liguria of500mLper 24 hours, pulmo-
ary edema or cyanosis, human immuno-
eficiency virus, use of intravenous anti-
ypertensive medication, fetal anomalies,
ntrauterine growth restriction, and ab-
ormal fetal-heart rate monitoring.
In the HYPITAT study, which was an-
lyzed according to intention to treat,
omen allocated to expectant monitor-
ng were induced if they developed se-
ere preeclampsia. Patients who refused
andomization were analyzed separately
fter informed consent as nonrandom-
zed patients.
he follow-up study
rom June 2008 through November
010, women who had participated in
he HYPITAT study were invited to par-
icipate in a longitudinal, follow-up
tudy assessing cardiovascular risk fac-
ors 2.5 years after pregnancy. We used a
ollow-up period of 2.5 years as this time
nterval allows using pregnancy as a
tress test to identify young women who
re at high risk for CVD in later life. Fur-
hermore, 2.5 years is long enough to en-
ure that pregnancy and lactation have
o influence on biochemical cardiovas-
ular risk factor levels. Three academic
ospitals and 17 nonacademic hospitals
cross 4 geographical regions in The s
JUNE 2013 Americetherlands (Leiden, Groningen, Am-
terdam, Brabant) participated.
ormotensive pregnancy cohort
he normotensive pregnancies at term
NTP) women were either friends of the
TP women or women from midwifery
ractices. NTP women were required to
ave had only uncomplicated normo-
ensive pregnancies. Exclusion criteria
or the NTP cohort included HELLP
yndrome, gestational hypertension,
reeclampsia, preexisting hypertension,
gestational) diabetes, premature deliv-
ry, delivery of a neonate with intrauter-
ne growth restriction (5th percentile),
enal disease, heart disease, and human
mmunodeficiency virus. Initially, we
sked HTP women if they had a friend
ho had given birth in the same period
s the HTP woman and who could func-
ion as NTP woman. We assumed that
riends would be similar in terms of age,
emographic region, and ethnic origin.
f an HTP woman did not have a friend
ho could function as NTP woman, we
earched for a NTP woman in a mid-
ifery practice of the same demographic
egion and matched for elapsed time
ince delivery. It is common practice in
he Netherlands for women with no
edical history or obstetrical history to
ave their antenatal care provided by a
idwife. Data were collected from their
edical records in midwifery practices.
e collected and reviewed the NTP
omen’s blood pressure measurements
nd their maternal and fetal outcomes of
ndex and previous pregnancies and de-
iveries in thorough detail. Relatives of
he HTPwomenwere excluded from the
TP cohort. Furthermore, women who
ere pregnant or lactatingwithin the last
months were excluded from our study
n 101).
ollow-up study procedure and
ardiovascular risk factor assessment
he study protocol has been previously
ublished.16 We refer to the Appendix
or a detailed description of the risk fac-
or assessment methods and the labora-
ory methods.
In short, local research nurses coun-eled the participants, obtained written
an Journal of Obstetrics& Gynecology 474.e2
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study protocol in each center, and col-
lected the data. After enrollment all
participants were invited for cardio-
vascular risk factor assessment, includ-
ing blood pressure measurement,
weight, height, and hip and waist
circumference. Furthermore, all par-
ticipants were asked to complete a
questionnaire. This questionnaire in-
cluded: medical history, current use of
medication, obstetric history, subse-
quent pregnancy after index preg-
nancy, and family history, including
CVD.
Venousbloodsampleswerecollectedaf-
ter an overnight fast and assayed for: glu-
cose, glycosylated hemoglobin (HbA1c),
nsulin, total cholesterol, high-density li-
oprotein (HDL) cholesterol, triglycer-
des, and high-sensitivity C-reactive pro-
ein (hs-CRP). Insulin resistance was
ssessed by the homeostatic model as-
essment (HOMA): insulin concentra-
ion/(22.5e–ln glucose concentration).18 Urine
was collected immediately after waking
up for assessment of microalbuminuria.
After immediately centrifuging, the
blood and urine samples were sent to a
central laboratory (Medical Center
Haaglanden, The Hague, The Nether-
lands) and were analyzed within 36
hours after blood draw.
Definitions
Hypertension 2.5 years’ postpartum was
defined as systolic blood pressure 140
mm Hg, diastolic blood pressure 90
mm Hg, or current use of antihyperten-
sivemedication.Major independent risk
factors were defined according to the
American Heart Association, including
blood pressure 140/90 mm Hg, HDL
cholesterol 40 mg/dL, current smok-
ing, and a family history of early CVD.19
Metabolic syndrome was defined as
waist circumference 80 cm plus any 2
of: raised triglycerides (150 mg/dL),
reduced HDL cholesterol (50 mg/dL),
raised bloodpressure (systolic130mm
Hg and diastolic 85 mm Hg), treat-
ment of previously diagnosed hyperten-
sion, raised fasting plasma glucose
(100 mg/dL), or previously diagnosed
type 2 diabetes.20
474.e3 American Journal of Obstetrics& GynecoloSample size considerations
Our power analysis was based on indi-
vidual risk estimation from the Framing-
ham Heart Study,21 rather than on car-
iovascular risk factors alone.22 Due to
the young age of our participants, the es-
timated absolute 10-year cardiovascular
risk was likely to be low. Therefore, our
approach was to estimate the risk for
each woman as if the woman was 60
years old. This approach has been rec-
ommended in the cardiovascular risk
factormanagement guidelines for young
women with elevated risk factor levels.23
For detecting an estimated absolute
10-year cardiovascular risk difference
between the HTP and NTP cohorts of
10% increase after extrapolation, we
needed a sample size of 456 women for
80% power and a 5% type 1 error prob-
ability (2-sided) for inclusion in 3:1 ratio
(3 HTP: 1 NTP). This method was used
according to an earlier study performed
in severe early preeclampsia.22 Accord-
ing to earlier studies24-26 we expected a
homogeneous effect with low prevalence
of unfavorable cardiovascular risk fac-
tors in NTP women. Therefore, we used
a 3:1 inclusion ratio instead of 1:1 as we
assumed that including more NTP
women in 1:1 ratio would have no addi-
TABLE 1
Baseline characteristics at index p
Characteristic
Maternal age, y
...................................................................................................................
Ethnic origin
..........................................................................................................
Caucasian
..........................................................................................................
Other
..........................................................................................................
Unknown
...................................................................................................................
Nulliparous
...................................................................................................................
Systolic blood pressure at booking, mm Hg
...................................................................................................................
Diastolic blood pressure at booking, mm Hg
...................................................................................................................
Body mass index at booking, kg/m2
...................................................................................................................
Gestational age at delivery, wk
...................................................................................................................
Birthweight, g
...................................................................................................................
Table shows mean (SD) or number (%). Differences between g
2 test.
HTP, hypertensive disorders at term pregnancy; NTP, normote
Hermes. Cardiovascular risk factors after hypertensive pretional value in this study as a result of
gy JUNE 2013homogeneous outcome of cardiovascu-
lar risks.
Statistical analysis
Data were analyzed using software
(SPSS, version 18.0; IBMCorp, Armonk,
NY). Baseline continuous data are ex-
pressed as means and SD or as medians
with 25th–75th percentile (interquartile
range) for the not normally distributed
values; dichotomous data are presented
as numbers and percentages. Differences
between groupswere testedwith the Stu-
dent t test and categorical data with 2
test. Comparisons of continuous data
with a skewed distribution were per-
formed using the nonparametric Mann-
Whitney U test. We used logistic regres-
sion analyses and results were reported
as odds ratios (ORs) with corresponding
95% confidence intervals (CIs). We
made adjustments for potential con-
founders, where appropriate, ie, parity,
body mass index (BMI), smoking, and
age at follow-up; and BMI, systolic and
diastolic blood pressure, and parity at
booking. Furthermore, we performed
a multicenter analysis that resulted in
an intraclass correlation coefficient of
2-4%. Therefore, we did not use a mul-
nancy
NTP cohort
(n  99)
HTP cohort
(n  306) P value
31 (4.5) 31 (5.1) .70
..................................................................................................................
..................................................................................................................
94 (95%) 273 (89%) .15
..................................................................................................................
5 (5%) 30 (10%)
..................................................................................................................
0 (0%) 3 (1%)
..................................................................................................................
30 (30%) 211 (69%)  .001
..................................................................................................................
113 (11) 120 (12)  .001
..................................................................................................................
66 (7.6) 73 (9.0)  .001
..................................................................................................................
24 (4.2) 26 (4.9)  .001
..................................................................................................................
39.9 (1.2) 39.4 (1.3)  .001
..................................................................................................................
3630 (465) 3395 (519)  .001
..................................................................................................................
s were tested with Student t test and categorical data with
e pregnancies at term.
cy disorders at term. Am J Obstet Gynecol 2013.reg
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
roup
nsivtilevel model for our analyses. For all
gnan
www.AJOG.org Obstetrics Researchtests, a P value .05 indicated statisti-
cal significance.
RESULTS
From June 2008 through November
2010, 306 womenwith a history of gesta-
tional hypertension or preeclampsia at
term and 99womenwith a history of un-
complicated normotensive pregnancies
TABLE 2
Outcome characteristics at 2.5-yea
Characteristic
Maternal age at follow-up, y
...................................................................................................................
Time elapsed since delivery, d
...................................................................................................................
Primiparous
...................................................................................................................
Antihypertensive medication use
...................................................................................................................
Systolic blood pressure at follow-up, mm Hg
...................................................................................................................
Diastolic blood pressure at follow-up, mm Hg
...................................................................................................................
Body mass index at follow-up, kg/m2
...................................................................................................................
Waist circumference, cm
...................................................................................................................
Hip circumference, cm
...................................................................................................................
Smoking
...................................................................................................................
Table shows mean (SD) or number (%). Differences between gr
2 test.
HTP, hypertensive disorders at term pregnancy; NTP, normote
Hermes. Cardiovascular risk factors after hypertensive pre
TABLE 3
Biochemical cardiovascular risk fa
Biochemical cardiovascular
risk factor
NTP co
(n  9
Microalbumin urine,a mmol/L 4.0 (
...................................................................................................................
Fasting blood glucose,b mg/dL 85 (79
...................................................................................................................
HbA1c,
c % 5.3 (
...................................................................................................................
Insulin,d mU/L 2.9 (
...................................................................................................................
HOMA scoree 0.6 (
...................................................................................................................
hs-CRP,f mg/L 0.9 (
...................................................................................................................
Total cholesterol,g mg/dL 178 (15
...................................................................................................................
HDL cholesterol,h mg/dL 56 (50
...................................................................................................................
Triglycerides,h mg/dL 63 (48
...................................................................................................................
HbA1c, glycosylated hemoglobin; HDL, high-density lipoprot
sensitivity C-reactive protein; HTP, hypertensive disorders at t
a Missing data of 6 NTP women and 9 HTP women; b Missing d
was caused by fact that urine and blood samples were only p
period were cancelled for analysis. Table showsmedian (inter
nonparametric Mann-Whitney U test. HTP women; c Missing
women and 24 HTP women; e Missing data of 11 NTP wome
women; g Missing data of 5 NTP women and 5 HTP womenHermes. Cardiovascular risk factors after hypertensive pregnanat term were included in the follow-up
study.
Of the 751 eligibleHTPwomen for the
2.5-year follow-up study, 168women re-
fused participation, 175 women were
lost to follow-up, and 101 pregnant or
lactating women were excluded. One
woman died in a car accident. The NTP
cohort consisted of 40 women who were
ollow-up
NTP cohort
(n  99)
HTP cohort
(n  306) P value
34 (4.7) 34 (5.2) .67
..................................................................................................................
965 (387) 921 (161) .11
..................................................................................................................
30 (30%) 123 (40%) .04
..................................................................................................................
0 (0%) 29 (9%)  .001
..................................................................................................................
110 (9.3) 124 (13)  .001
..................................................................................................................
72 (8.8) 82 (9.6)  .001
..................................................................................................................
24 (4.6) 28 (5.5)  .001
..................................................................................................................
81 (12) 90 (13)  .001
..................................................................................................................
104 (11) 109 (12)  .001
..................................................................................................................
19 (19%) 60 (20%) .89
..................................................................................................................
were tested with Student’s t test and categorical data with
e pregnancies at term.
cy disorders at term. Am J Obstet Gynecol 2013.
rs 2.5 years after pregnancy
t HTP cohort
(n  306) P value
8.0) 5.0 (3.0–10.0) .06
..................................................................................................................
) 85 (81–92) .01
..................................................................................................................
5.5) 5.3 (5.1–5.6) .04
..................................................................................................................
5.0) 4.4 (2.0–7.6) .003
..................................................................................................................
1.0) 1.0 (0.4–1.6) .001
..................................................................................................................
2.2) 2.2 (1.0–5.0)  .001
..................................................................................................................
97) 182 (162–207) .02
..................................................................................................................
) 54 (46–62) .03
..................................................................................................................
) 81 (58–110)  .001
..................................................................................................................
HOMA, homeostatic model assessment; hs-CRP, high-
pregnancy; NTP, normotensive pregnancies at term.
f 11 NTP women and 15 HTP women. Majority of missing data
sed within 36 h after sampling. Samples that arrived after this
tile range, 25th–75th percentile). Differences were tested with
of 6 NTP women and 14 HTP women; d Missing data of 9 NTP
25 HTP women; f Missing data of 7 NTP women and 10 HTP
issing data of 5 NTP women and 4 HTP women.cy disorders at term. Am J Obstet Gynecol 2013.
JUNE 2013 Americfriends of the HTP women and 59
women who were identified from mid-
wifery practices.
Baseline characteristics of the subjects
are shown in Table 1. At index preg-
nancy, HTP women were more often
nulliparous and had higher BMI at
booking, higher systolic and diastolic
blood pressures at booking, lower gesta-
tional age at delivery, and lower birth-
weight compared with NTP women.
At the 2.5-year follow-up study, HTP
women were found to use more antihy-
pertensive medication and had higher
BMI, higher systolic and diastolic blood
pressures, and higher waist circumfer-
ences compared with NTP women.
There were no significant differences in
maternal age, elapsed time since deliv-
ery, or smoking rates (Table 2).
Table 3 shows biochemical cardiovas-
cular risk factors 2.5 years after index
pregnancy in HTP and NTP women.
Fasting blood glucose, HbA1c, insulin,
HOMA scores, total cholesterol, triglyc-
erides, and hs-CRP were all significantly
higher in HTP compared with NTP
women. HDL cholesterol was signifi-
cantly lower in HTP women. We found
higher microalbumin levels in urine in
HTP women, however this difference
was not significant (P .06).
The prevalence of 4 major cardiovas-
cular risk factors, multiplemajor cardio-
vascular risk factors, and metabolic syn-
drome in HTP and NTP women are
summarized in Table 4. The adjustedOR
of HTP women for hypertension 2.5
years’ postpartum was 48. On the con-
trary, there were no significant differ-
ences between HTP and NTP women in
the other 3 major independent risk fac-
tors: HDL cholesterol, currently smok-
ing, or family history of early CVD.Mul-
tiple risk factors were present in 18% of
the HTP women compared with 7% of
NTP women (P  .01), including 4%
of HTP women with 3 independent
risk factors compared to 0% in NTP
women. Metabolic syndrome was found
in 25% of HTP and in 5% of NTP
women (OR, 6.0; 95%CI, 2.3–15.3) even
after adjustment for maternal age and
baseline differences.
Surprisingly, we found a prevalence ofr f
.........
.........
.........
.........
.........
.........
.........
.........
.........
.........
oups
nsivcto
hor
9)
3.0–
.........
–88
.........
5.1–
.........
2.0–
.........
0.4–
.........
0.4–
.........
1–1
.........
–63
.........
–91
.........
ein;
erm
ata o
roces
quar
data
n and
; h Mchronic hypertension of 34% in the HTP
an Journal of Obstetrics& Gynecology 474.e4
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Research Obstetrics www.AJOG.orgcohort 2.5 years’ postpartum, of which 29
women (28%) had started antihyperten-
sive medication at 2.5 years after preg-
nancy. This unexpected high prevalence
might partially be explained by inclusion
TABLE 4
Major independent cardiovascular
Independent CVD risk factor and
metabolic syndrome
NTP
(n 
Blood pressure,c 140/90 mm Hg 1 (1
...................................................................................................................
HDL cholesterol,e 40 mg/dL 10 (1
...................................................................................................................
Current smoking,f % 19 (1
...................................................................................................................
Family history of early CVD,h % 11 (1
...................................................................................................................
1 independent risk factore 32 (3
...................................................................................................................
2 independent risk factorse 7 (7
...................................................................................................................
Metabolic syndromej 5 (5
...................................................................................................................
Logistic regression analyses; adjustments made for potential co
36 h after sampling. Samples that arrived after this period we
CI, confidence interval; CVD, cardiovascular disease; HDL, hig
a Adjusted for parity, body mass index (continuous variable), sm
at booking, and parity at booking; c Missing data of 1 HTP w
NTP women and 13 HTP women; g Adjusted for age; h Missin
for age, parity, and smoking.
Hermes. Cardiovascular risk factors after hypertensive pre
TABLE 5
Prevalence of hypertension per blo
postpartum
Cutoff value for subgroup based on blood
MAP at booking 100 mm Hg
..........................................................................................................
Criterion
..........................................................................................................
No of women (%)
..........................................................................................................
Prevalence of hypertension 2.5 y postpart
...................................................................................................................
MAP at booking 90 mm Hg
..........................................................................................................
Criterion
..........................................................................................................
No of women (%)
..........................................................................................................
Prevalence of hypertension 2.5 y postpart
...................................................................................................................
Blood pressure at booking 130/75 mm Hg
..........................................................................................................
Criterion
..........................................................................................................
No of women (%)
..........................................................................................................
Prevalence of hypertension 2.5 y postpart
...................................................................................................................
Blood pressure at booking 120/70 mm Hg
..........................................................................................................
Criterion
..........................................................................................................
No of women (%)
..........................................................................................................
Prevalence of hypertension 2.5 y postpart
...................................................................................................................
Table shows number (%).
MAP, mean arterial pressure.Hermes. Cardiovascular risk factors after hypertensive pregnan
474.e5 American Journal of Obstetrics& Gynecoloin the HYPITAT study of some women
with chronic hypertension, which was ini-
tially masked by the physiological fall of
blood pressure in early pregnancy. There-
fore, we performed subanalyses and di-
k factors, multiple risk factors, and m
ort HTP cohort
(n  306)
Unadjusted OR
(95% CI)
A
(9
105 (34%) 51.5 (7.1–374) 4
.........................................................................................................................
) 37 (12%) 1.2 (0.6–2.5)
.........................................................................................................................
) 60 (21%) 1.1 (0.6–1.9)
.........................................................................................................................
) 48 (16%) 1.6 (0.8–3.1)
.........................................................................................................................
) 184 (61%) 3.0 (1.9–4.9)
.........................................................................................................................
54 (18%) 2.7 (1.2–6.2)
.........................................................................................................................
73 (25%) 6.0 (2.3–15)
.........................................................................................................................
nders 2.5 y after pregnancy. Majority of missing data was caused
ncelled for analysis. Table shows number (%) and OR (95% CI).
nsity lipoprotein; HTP, hypertensive disorders at term pregnancy;
g, age at follow-up; b Adjusted for differences at baseline, including
; d Adjusted for age, body mass index, parity, and smoking; e Mis
ta of 1 NTP women and 14 HTP women; i Adjusted for age and par
cy disorders at term. Am J Obstet Gynecol 2013.
pressure subgroup 2.5 years’
ssure at booking in index pregnancy
..................................................................................................................
Yes No
..................................................................................................................
35 (11%) 271 (89%)
..................................................................................................................
57% 32%
..................................................................................................................
..................................................................................................................
Yes No
..................................................................................................................
147 (48%) 159 (52%)
..................................................................................................................
44% 25%
..................................................................................................................
..................................................................................................................
Yes No
..................................................................................................................
167 (55%) 139 (45%)
..................................................................................................................
44% 23%
..................................................................................................................
..................................................................................................................
Yes No
..................................................................................................................
251 (82%) 55 (18%)
..................................................................................................................
36% 27%
..................................................................................................................t
cy disorders at term. Am J Obstet Gynecol 2013.
gy JUNE 2013vided the HTP cohort into mean arterial
pressure at booking and blood pressure at
booking subgroups. As can be seen from
Table 5, even when we studied the sub-
groupofwomenwhohadabloodpressure
of120/70 mmHg at booking, the prob-
bility of hypertension after 2.5 years was
till as high as 27%. In all, 94 HTPwomen
31%) had developed severe hypertensive
isease during their index pregnancy.
COMMENT
The main finding of the follow-up study
is that women with a history of gesta-
tional hypertension or preeclampsia at
term have a high risk of hypertension 2.5
years after their pregnancy. Additionally,
women with a history of gestational hy-
pertension or preeclampsia at term ex-
hibitmore cardiovascular risk factors 2.5
years after their pregnancy compared
with women with a history of uncompli-
cated normotensive pregnancies. They
have higher waist circumferences; higher
BMI; higher systolic and diastolic
blood pressures; higher prevalence of
metabolic syndrome; higher levels of
biochemical risk factors, including
glucose, HbA1c, insulin, insulin resis-
ance (HOMA), total cholesterol, trig-
ycerides, and hs-CRP; and lower levels
f HDL cholesterol 2.5 years’ postpar-
um compared with women with a his-
tabolic syndrome
sted ORa
CI)
Adjusted ORb
(95% CI) P value
(6.5–350) 36.4 (4.8–276)  .001
..................................................................................................................
(0.3–1.8) 1.1 (0.4–2.8) .53
..................................................................................................................
g (0.6–1.1) 1.1 (0.5–2.1) .98
..................................................................................................................
(0.8–3.5) 2.0 (0.9–4.2) .15
..................................................................................................................
(1.9–5.3) 2.7 (1.5–4.9)  .001
..................................................................................................................
(1.3–7.5) 3.0 (1.0–9.0) .01
..................................................................................................................
(2.3–15) 3.3 (1.2–9.1)  .001
..................................................................................................................
t that urine and blood samples were only processed within
, normotensive pregnancies at term; OR, odds ratio.
y mass index at booking, systolic and diastolic blood pressures
data of 5 NTP women and 4 HTP women; f Missing data of 1
Missing data of 4 NTP women and 14 HTP women; k Adjustedris e
coh
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www.AJOG.org Obstetrics ResearchOur results after hypertensive preg-
nancy disorders at term are in line with
results from previous studies. These
studies reported higher blood pressure,
higher BMI, and higher concentrations
of lipids and insulin resistance in women
with previous hypertensive pregnancy
disorders.7,24,27-46 However, previous
tudies included onlywomenwith severe
reterm preeclampsia,29,36,37 gestational
ge was not reported,27,28,38,39,41,42,45
and distinction was not made between
preterm preeclampsia and term pre-
eclampsia.24,32-34,38,40,43,44,46 This makes
it difficult to draw a conclusion about the
association of hypertensive disorders in
term pregnancy and the presence of car-
diovascular risk factors after pregnancy.
In the literature, 2 other studies have
determined cardiovascular risk factors
after “mainly” term hypertensive pre-
gnancy disorders.34,43 These studies
showed similar results to our study, de-
spite the fact that both studies are small
(n  43 and n  30, respectively). Dif-
erences between our study and previous
tudies can be explained by differences in
ollow-up periods, study population (eg,
ulliparous and multiparous women),
r chronic hypertension. While other
tudies, which mostly included women
ith severe pretermpreeclampsia, found
ignificantly higher microalbumin levels
ostpartum compared to control sub-
ects (mean difference, 8.55; 95% CI,
.11–14.98),47we showed a trend toward
igher microalbumin levels in HTP
omen compared to NTP women (P 
06). Due to the sample size, our finding
id not reach statistical significance.
We found an unexpected high preva-
ence of hypertension 2.5 years’ postpar-
um in the HTP cohort, namely 34%
ompared with 1% in the NTP cohort.
he high prevalence was unexpected,
specially because women with preex-
sting hypertension with antihyperten-
ive medication use (before index preg-
ancy) were excluded from our study.
ue to physiological blood pressure re-
uction in the first trimester, inclusion
f womenwith (sub) clinical chronic hy-
ertension without the use of antihyper-
ensive medication might explain, at
east partly, the high prevalence of
ypertension 2.5 years’ postpartum in lur study. However, the prevalence of
hronic hypertension 2.5 years’ postpar-
um in the lowest blood pressure at
ooking subcategory 130/75 mm Hg
as still as high as 23% and thus of clinical
nterest. We assumed that women with a
lood pressure at booking 130/75 mm
gdonot have chronic hypertension. An-
ther consideration is that we performed
he follow-up of only 306 HTP women
27%of theHYPITATcohort [n1153]),
hich might have resulted in selection
ias. The selection bias might result in an
verestimation of the prevalence of
hronic hypertension in HTP women.
owever, the fact that women who were
ot included in the follow-up study had
igher diastolic blood pressures at book-
ng compared to includedwomen argues
gainst overestimation of chronic hyper-
ension in HTP women. Women who
ere included in the follow-up study
ere significantly older at baseline com-
ared to women who were not included.
ll other baseline characteristics were
omparable between included and non-
ncludedwomen (data not shown). If the
esulting 847 women, who were not in-
luded in the follow-up study, would all
ave been normotensive 2.5 years’ post-
artum, we would have introduced the
ost extreme selection bias. Even then,
he minimum detection rate for chronic
ypertension for HTP women is 9%. To
ut these percentages in perspective: the
revalence of chronic hypertension in
he Netherlands, among women in a
omparable age group between 30-40
ears in 2010, was 5.5%. Thus, a detec-
ion rate between aminimum of 9% and
maximumof 34% inwomenwith a his-
ory of gestational hypertension or pre-
clampsia at term is of great interest for
ealth care providers.
The major strength of our study is
-fold. First, we focused on women with
history of hypertensive pregnancy dis-
rders at term, which are common dis-
rders in pregnancy and of daily ob-
tetric care. Second, we longitudinally
ollowed up HTP women who were in-
luded in a randomized controlled trial
nd we had a prespecified hypothesis
nd objective at baseline, providing a
arge and strong HTP cohort. t
JUNE 2013 AmericThe finding, that the common preg-
ancy disorders gestational hypertension
nd preeclampsia at term are associated
ith a high risk of hypertension andmore
ardiovascular risk factors, makes this
tudy original and of interest for not only
bstetricians, but also for internists, cardi-
logists, and general physicians.
Our study has a few limitations. First,
he study design of theHYPITAT trial was
o compare 2 different strategies at term in
omen with 1 pregnancy complication,
amely gestational hypertension or pre-
clampsia, without comparison to a con-
rol group.Tocomparecardiovascular risk
actors after 2.5 years, we secondarily
dded a control group. For that purpose,
aseline data of the index pregnancy of
TPwomenwere collected fromreviewof
edical records at the time of inclusion in
he follow-up study. The information on
he variables addressed in this manuscript
as nearly all complete in the medical
harts. HTP and NTP women were com-
arable according to age, race, and demo-
raphic region. From etiological perspec-
ive, it would have been ideal to have
atchedHTPandNTPwomenforBMIat
ooking, blood pressure at booking, and
arity. Instead, we preferred a pragmatic
pproach as we aimed to study whether
ypertensive pregnancy disorders in term
regnancy can be used as a stress test for
ardiovascular risk factor screening to
dentify women who are at risk for CVD
ater.Weperformedamultivariateanalysis
aking all the differences at baseline into
ccount (Table 4). The results of that ap-
roach showed that even after adjustment
or baseline factorsHTPwomenhad a sig-
ificantly higher prevalence of hyperten-
ion andmetabolic syndrome 2.5 years af-
er pregnancy. A problem with a
ultivariatemodel like that is that the dif-
erences were based on definitions of the
ohort.However, itdoesnot invalidateour
ndings showing that women with a his-
ory of hypertensive pregnancy disorders
t term still have unfavorable risk factors
.5 years after pregnancy.
A second limitation concerns the vol-
ntary contribution of NTP women,
hich may have introduced selection
ias. NTP women with a family history
f CVD are probably more likely to par-
icipate in a study on risk of CVD than
an Journal of Obstetrics& Gynecology 474.e6
Research Obstetrics www.AJOG.orgwomen with a healthy family history.
However, family history of first degrees
with a cardiovascular event60 years of
age was not significantly different be-
tween both groups. Moreover, this po-
tential bias underestimates the differ-
ences between HTP and NTP women.
Finally, asaconsequenceof therelatively
young age of the study participants, this
study evaluated surrogate endpoints: car-
diovascular risk factors rather than cardio-
vascular clinical outcomes.
Our study results strongly suggest
that women with a history of gesta-
tional hypertension or preeclampsia at
term may be offered screening and
counseling for cardiovascular risk fac-
tors after their pregnancy. Before wide
implementation in practice however,
strategies of cardiovascular risk factor
screening and subsequent tailored pre-
ventive interventions need to be evalu-
ated for feasibility, clinical effective-
ness, and cost-effectiveness.
Clara Kolster, research nurse from the
Department of Obstetrics at the Leiden
University Medical Center, Leiden, The
Netherlands, is acknowledged for her
contribution to the study. f
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APPENDIX
Detailed description of the risk factor
assessment methods and the
laboratory methods
HypertensionRiskAssessment Study
procedure and cardiovascular risk
factor assessment
Local research nurses counseled the par-
ticipants, obtained written informedconsent, monitored the study protocol
in each center, and collected the data. Af-
ter enrollment, all participants were in-
vited to their local center for cardiovas-
cular risk factor assessment and were
asked to complete a questionnaire. This
questionnaire included questions about
their medical history, current use of
medication, obstetric history, subse-
quent pregnancy after index pregnancy,
and family history, including cardiovas-
cular disease.
Assessment of cardiovascular risk fac-
tors was performed by trained research
nurses in their respective local centers.
Blood pressure was measured manually
with a validated sphygmomanometer in
sitting position at the right upper arm
using the equipment and methodology
of the Hypertension and Preeclampsia
Intervention Trial at Term (HYPITAT)
study. The mean of 2 measurements was
used in the analyses. Height and weight
weremeasured wearing light clothes and
shoes (no heels); height wasmeasured to
the nearest 1 cm and weight to the near-
est 1 kg. Body mass index was calculated
as weight/length2; hip and waist circum-
erence were measured with the partici-
ant standing upright, using a steel band
o measure horizontally at the height of
he umbilicus, and rounded to the near-
st 1 cm. Venous blood samples were
ollected after an overnight fast and as-
ayed for glucose, glycosylated hemoglo-
in (HbA1c), insulin, total cholesterol,
high-density lipoprotein (HDL) choles-
terol, triglycerides, and high-sensitivity
C-reactive protein (hs-CRP). Insulin re-
sistance was assessed by the homeostatic
model assessment: insulin concentra-
tion/(22.5e-ln glucose concentration).20 Urine
was collected for assessment of mi-
croalbuminuria immediately after wak-
ing up. After immediate centrifuging,
the blood and urine samples were sent to
a central laboratory (Medical Center
Haaglanden, The Hague, The Nether-
lands) and analyzed within 36 hours af-
ter blood draw.
JUNE 2013 AmericLaboratory methods
We used a Modular P800, E170 analyzer
and corresponding reagents (Roche Di-
agnostics, Almere, The Netherlands) to
determine blood plasma levels of glucose
(in a tube containing sodium fluoride),
total cholesterol, HDL cholesterol, trig-
lycerides, and urine concentrations of al-
bumin.HbA1c levels in bloodwere deter-
mined by high-performance lipid
chromatography on a Variant II Turbo
(Bio-Rad, Veenendaal, The Nether-
lands) using corresponding buffers and
reagents. Insulin serum levels were de-
termined using an enzyme-labeled im-
munometric assay on the Immulite 2000
and corresponding reagents (Siemens
Healthcare Diagnostics, Breda, The
Netherlands). For theanalysisofhs-CRPa
plasma sample was snap frozen at70°C
ntil the batch analysis was performed.
lucose was measured spectrophoto-
etrically with an enzymatic hexokinase
ethod, and total cholesterol and trig-
ycerides with an enzymatic colorimet-
ic method. HbA1c was separated from
ther hemoglobin forms on a cation
xchange column and detected spec-
rophotometrically. HDL cholesterol
evels were quantified using an enzy-
atic colorimetric test after complex-
tion of the chylomicrons, low density
ipoprotein and very low density lipo-
rotein cholesterol with dextran sul-
ate and magnesium sulfate. The hs-
RP levels were determined with a
article-enhanced immunoturbidimet-
ic assay. Microalbumin levels in urine
ere measured turbidimetrically after
gglutination with sheep antihuman al-
umin antibodies. Interassay coeffi-
ients of variationwere 0.9-1.0% for glu-
ose, 0.8-1.3% for HbA1c, 4.1-6.4% for
insulin, 0.8-0.9% for total cholesterol,
2.1-3.0% for HDL cholesterol, 1.0% for
triglycerides, 1.5-3.2% for hs-CRP, and
1.4-5.5% for microalbumin. All analyses
were performedby technicianswhowere
blinded for outcome.
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